Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

NCT04250051 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

2

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Acute Myeloid Leukemia
Recurrent Myelodysplastic Syndrome
Recurrent Myeloproliferative Neoplasm
Refractory Acute Myeloid Leukemia
Refractory Myelodysplastic Syndrome

Interventions

DRUG: Cytarabine
BIOLOGICAL: Filgrastim
DRUG: Fludarabine
DRUG: Fludarabine Phosphate
DRUG: Ivosidenib

Sponsor

Northwestern University

Collaborators

[object Object]